| Autor: |
Yakovenko EP; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia., Agafonova NA; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia., Ivanov AN; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia., Yakovenko AV; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia., Aldiyarova MA; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia., Volosheinikova TV; Clinical Hospital, Department for Presidential Affairs of the Russian Federation, Moscow, Russia., Grigoryeva YV; Clinical Hospital, Department for Presidential Affairs of the Russian Federation, Moscow, Russia., Soluyanova IP; Amusk State Medical Academy, Ministry of Health of Russia, Blagoveshchensk, Amursk Region. |
| Abstrakt: |
Rebamipide is a cytoprotесtive drug that stimulates the generation of endogenous prostaglandins in the gastric and small intestinal mucosa and accelerates the healing of erosions and ulcers caused by Helicobacter pylori infection and NSAID administration. The major properties of rebamipide include stimulation of prostaglandins and synthesis of muсus glycoproteins, inhibition of reactive oxygen species, inflammatory cytokines, and chemokines, and suppression of neutrophil activation. This paper shows the ability of rebamipide to enhance the efficiency of therapy for Helicobacter pylori-induced infection, to reduce inflammation, including that after infection eradication, to accelerate ulcer healing, and to prevent the progression of preneoplastic lesions. |
